Key result
Simulated dysphagia therapy yields ~2.6-fold higher odds of 90-day quality-of-life responder success.
Why the study?
Trials evaluating interventions for post-stroke dysphagia face challenges in selecting endpoints that are both patient-centered and methodologically robust.
Does a severity-anchored, dichotomous PRO responder endpoint combining SWAL-QOL and EQ-5D improve statistical efficiency and clinical interpretability compared with continuous SWAL-QOL or UW-mRS in simulated trials of post-stroke dysphagia?
Does a severity-anchored, dichotomous PRO responder endpoint combining SWAL-QOL and EQ-5D improve statistical efficiency and clinical interpretability compared with continuous SWAL-QOL or UW-mRS in simulated trials of post-stroke dysphagia?
Answers are grounded in this paper and cite their sources.
A baseline NIHSS severity-calibrated, dichotomous 90-day PRO responder endpoint combining SWAL-QOL and EQ-5D substantially improves sensitivity and statistical efficiency over continuous PROs or global disability scales (UW-mRS) for post-stroke dysphagia clinical trials.
Background: Post-stroke dysphagia is common and is associated with aspiration pneumonia, malnutrition, longer hospitalization, and reduced quality of life. Trials evaluating interventions for post-stroke dysphagia face persistent challenges in selecting endpoints that are both patient-centered and methodologically robust. Objectives: To derive and justify a patient-reported outcome (PRO) endpoint for stroke-related dysphagia that supports clinically meaningful interpretation, statistical efficiency, and alignment with regulatory expectations. Methods: We synthesized regulatory guidance, outcomes-research standards, and stroke-specific evidence to develop a dichotomous, status-based PRO responder endpoint at 90 days post-stroke that integrates swallowing-specific quality of life (SWAL-QOL) and global health-related quality of life (EuroQol-5D; EQ-5D). Responder definitions were calibrated to baseline dysphagia severity using swallowing-relevant National Institutes of Health Stroke Scale (NIHSS) subcomponents assessed in the early post-acute period. Monte Carlo simulations (10,000 simulated patients with post-stroke dysphagia) compared performance of the combined responder endpoint versus (i) continuous SWAL-QOL and (ii) utility-weighted modified Rankin Scale (UW-mRS) analyses under clinically realistic severity distributions and treatment effects. Sample size requirements were estimated for individually randomized and stepped-wedge designs. Results: Severity-anchored responder endpoints were more statistically efficient and more interpretable than continuous or change-based analyses in heterogeneous acute stroke populations. In simulation, combined SWAL-QOL + EQ-5D responder rates increased from 42.7% (control) to 66.2% (treatment), an absolute difference of 23.5% (odds ratio 2.58, 95% CI 2.38-2.81; number needed to treat ≈ 4-5), with the largest effects in moderate and severe dysphagia. In contrast, mean SWAL-QOL improved by 8.3 points (near or below commonly cited minimal clinically important difference thresholds), and mean UW-mRS improved by 0.017, indicating limited sensitivity of global disability measures. Conclusion: A severity-calibrated, dichotomous PRO responder endpoint combining SWAL-QOL and EQ-5D provides a patient-centered, statistically efficient, and methodologically robust framework for evaluating therapeutic interventions in post-stroke dysphagia.
No takes yet. Share an insight, caveat, or question.
Qureshi et al. (2026) studied Post-stroke dysphagia (n=10,000). Simulated dysphagia-targeted therapeutic intervention evaluated via a severity-anchored SWAL-QOL + EQ-5D PRO responder framework vs. Simulated control (usual care) and comparator endpoint analyses (continuous SWAL-QOL and UW-mRS) was evaluated on Severity-calibrated dichotomous PRO responder status at 90 days post-stroke requiring concordant success on both SWAL-QOL and EQ-5D (OR 2.58, 95% CI 2.38-2.81). Simulated dysphagia treatment increased 90-day severity-calibrated SWAL-QOL + EQ-5D responder rates from 42.7% to 66.2%.
Synapse has enriched 10 related papers. Consider them for comparative context: